总的来说，值得授予专利的发明和发现是在制药和生物技术领域，在该领域每年都能推出价值可达数十亿美元，影响重大的新药。
By and large, the inventions and discoveries worth patenting are those in the pharmaceutical and biotech fields, where the pay-off for blockbuster drugs can amount to billions of dollars a year.
瑞士有非常严密的知识产权法律对商标和发明的保护特别强这是由于瑞士传统上一直致力于保护他们的生物技术企业。
Watertight IP laws, protecting brands and inventions, are particularly strong in Switzerland thanks to the country's strong tradition of innovative biotech enterprises.
但是，如果专利就像在生物技术，遗传学和其它学科领域发生的那样，实际上阻碍了将各项发明组合与再组合，以产生新的产品和工艺，那又如何来评价它哪？
But what if patents actually discourage the combining and recombining of inventions to yield new products and processes-as has happened in biotechnology, genetics and other disciplines?
应用推荐